Dec 30 The number of new drugs approved in the
United States fell in 2013 compared with the previous year as
fewer applications were filed, though several products for
hard-to-treat diseases were approved in record time.
The U.S. Food and Drug Administration approved 27 new drugs
in 2013, down from a banner year in 2012 which saw 39 drugs
approved, the greatest number since 1997 according to FDA data.
The regulatory agency attributed the drop in approvals in
2013 to fewer applications. As of Dec. 11, 32 applications had
been filed, compared with 41 for 2012, the FDA said. Over the
past five years, the average number of new drug filings per year
In July 2012, as part of the Food and Drug Administration
Safety and Innovation Act, the FDA introduced the "breakthrough
therapy" designation to help speed drugs to market that treat
serious or life-threatening conditions and where preliminary
evidence suggests the drug may work better than existing
The FDA's Center for Drug Evaluation and Research (CDER) has
received 120 requests for breakthrough therapy designation, of
which it has granted 36 requests and denied 58. The remainder
were pending or withdrawn at the end of the year.
The agency has approved three products so far under the
breakthrough therapy program: Roche Holding AG's
leukemia drug Gazyva; Johnson & Johnson's drug Imbruvica
for mantle cell lymphoma, a rare form of non-Hodgkin lymphoma;
and Gilead Sciences Inc's hepatitis C drug Sovaldi.
The number of drugs approved by CDER in 2013, though down
from 2012, is close to the historical average over the past five
years of 28, according to a recent FDA industry presentation.
The average internal rate of return from pharmaceutical
research and development fell to around 4.8 percent in 2013 from
7.2 percent last year and 10.5 percent in 2010, according to a
study released earlier this month by Deloitte and Thomson
Over the same four-year period, the average cost of
developing new medicines rose 18 percent to $1.3 billion, the
report found. Yet the average peak sales forecast for each new
drug dropped 43 percent to $466 million in 2013 from $816
million in 2010, the report found.
Nonetheless, some analysts remain optimistic that output
will increase along with advances in science.
"We are confident that changes to R&D strategies ... will
drive a significant improvement in output over the next decade,"
a Deutsche Bank report said this month.